9^thInternational Conference on
Dementia and Dementia Care

There are more than 5.5 million people in the US and 43 million people worldwide that have Alzheimer’s disease in 2017. Growth in the prevalence of Alzheimer’s disease (AD) over the next few decades is anticipated to result in great pressure on the social and health-care systems of developed and developing economies alike. The current treatment options are considered to be symptomatic.  There is an unmet need for therapies that halt or substantially slow disease progression. There were no new drug approvals for treatment of AD; none have been approved in the USA since 2003. Over the past 20 years a majority of failed AD drugs were based on the guiding principle of the Amyloid hypothesis, which postulates that accumulation of amyloid plaques trigger a cascade that harms neurons and synapses.  Most immunotherapy drugs based on β-secretase, γ-secretase, and  stimulators of α–secretase have been used to target Aβ  pathology include decreasing of Aβ  production, preventing aggregation of, or stimulating clearance of Aβ.  We will highlight a new non-amyloid approach in the development of a new drug in Phase 2 known as NA-831, a novel neuroprotective and neurogenesis agent, for treatment of Alzheimer's disease. The lesson learned from the past AD drug development failure and a new clinical strategy for the development of NA-831 will be presented and discussed.